Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.06
+0.03000.25%
Post-market: 12.130.0652+0.54%19:46 EDT
Volume:5.32M
Turnover:64.00M
Market Cap:1.69B
PE:-3.60
High:12.24
Open:11.96
Low:11.75
Close:12.03
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.26
T/O Rate:3.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.32
PE(LYR):-3.17

Loading ...

Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term

THOMSON REUTERS
·
Sep 04

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 04

Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

TIPRANKS
·
Sep 03

Intellia Therapeutics (NTLA) Stock May Be Fully Priced Despite Its 92% Slide

Simply Wall St.
·
Aug 27

Intellia Therapeutics Price Target Maintained with a $30.00/Share by Citizens

Dow Jones
·
Aug 25

Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today

TIPRANKS
·
Aug 25

Intellia CEO John M. Leonard Disposes of USD 286,764 in Common Shares

Reuters
·
Aug 25

Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target

TIPRANKS
·
Aug 15

Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees

Reuters
·
Aug 08

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)

TIPRANKS
·
Aug 07

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

Solid Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Reuters
·
Aug 07

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating

MT Newswires Live
·
Aug 06

Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Loss $0.80 a Share, vs. FactSet Est of $0.80 Loss

MT Newswires Live
·
Aug 06

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million

Reuters
·
Aug 06